Werewolf Therapeutics (HOWL) Competitors $1.25 +0.03 (+2.03%) As of 11:59 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOWL vs. DBVT, AVTE, YMAB, ACTU, ENGN, SCPH, CTMX, DRUG, CRGX, and IPHAShould you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include DBV Technologies (DBVT), Aerovate Therapeutics (AVTE), Y-mAbs Therapeutics (YMAB), Actuate Therapeutics (ACTU), enGene (ENGN), scPharmaceuticals (SCPH), CytomX Therapeutics (CTMX), Bright Minds Biosciences (DRUG), CARGO Therapeutics (CRGX), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry. Werewolf Therapeutics vs. Its Competitors DBV Technologies Aerovate Therapeutics Y-mAbs Therapeutics Actuate Therapeutics enGene scPharmaceuticals CytomX Therapeutics Bright Minds Biosciences CARGO Therapeutics Innate Pharma Werewolf Therapeutics (NASDAQ:HOWL) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings. Which has higher valuation & earnings, HOWL or DBVT? Werewolf Therapeutics has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWerewolf Therapeutics$1.14M49.27-$37.37M-$1.67-0.75DBV Technologies$15.73M16.82-$72.73M-$4.92-1.96 Is HOWL or DBVT more profitable? Werewolf Therapeutics has a net margin of -578.80% compared to DBV Technologies' net margin of -815.73%. Werewolf Therapeutics' return on equity of -58.83% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics-578.80% -58.83% -38.45% DBV Technologies -815.73%-106.07%-76.17% Does the MarketBeat Community prefer HOWL or DBVT? DBV Technologies received 374 more outperform votes than Werewolf Therapeutics when rated by MarketBeat users. However, 68.63% of users gave Werewolf Therapeutics an outperform vote while only 54.17% of users gave DBV Technologies an outperform vote. CompanyUnderperformOutperformWerewolf TherapeuticsOutperform Votes3568.63% Underperform Votes1631.37% DBV TechnologiesOutperform Votes40954.17% Underperform Votes34645.83% Do insiders and institutionals hold more shares of HOWL or DBVT? 64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 1.4% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to HOWL or DBVT? In the previous week, DBV Technologies had 1 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 4 mentions for DBV Technologies and 3 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.81 beat DBV Technologies' score of 0.76 indicating that Werewolf Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DBV Technologies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer HOWL or DBVT? Werewolf Therapeutics presently has a consensus target price of $8.33, indicating a potential upside of 564.01%. DBV Technologies has a consensus target price of $14.75, indicating a potential upside of 52.69%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Werewolf Therapeutics is more favorable than DBV Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00DBV Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk and volatility, HOWL or DBVT? Werewolf Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -0.63, suggesting that its share price is 163% less volatile than the S&P 500. SummaryWerewolf Therapeutics beats DBV Technologies on 13 of the 17 factors compared between the two stocks. Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOWL vs. The Competition Export to ExcelMetricWerewolf TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.32M$6.92B$5.60B$8.61BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.828.8427.2219.97Price / Sales49.27255.17408.95152.58Price / CashN/A65.8538.2534.64Price / Book0.416.587.114.68Net Income-$37.37M$144.20M$3.24B$248.05M7 Day Performance2.03%3.32%2.47%2.40%1 Month Performance25.50%10.53%8.66%6.14%1 Year Performance-59.12%3.63%31.22%13.62% Werewolf Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOWLWerewolf Therapeutics3.9512 of 5 stars$1.26+2.0%$8.33+564.0%-61.6%$56.32M$1.14M-0.8240Positive NewsGap UpDBVTDBV Technologies3.4424 of 5 stars$7.74-7.3%$14.75+90.6%+72.7%$212.00M$15.73M-1.7280News CoverageGap UpAVTEAerovate Therapeutics1.8506 of 5 stars$7.25+2.3%$78.75+986.2%-99.1%$210.14MN/A-2.4220Positive NewsHigh Trading VolumeYMABY-mAbs Therapeutics3.7663 of 5 stars$4.74+3.0%$15.60+229.1%-59.0%$208.31M$88.66M-8.78150Positive NewsAnalyst RevisionACTUActuate TherapeuticsN/A$10.59-11.0%$20.50+93.6%N/A$207.78MN/A0.0010High Trading VolumeENGNenGene2.6345 of 5 stars$3.98+3.6%$23.29+485.1%-63.2%$202.89MN/A-6.8631Earnings ReportGap UpSCPHscPharmaceuticals4.4956 of 5 stars$3.84+5.5%$14.00+264.6%-0.7%$202.72M$41.98M-2.0230Positive NewsCTMXCytomX Therapeutics4.3005 of 5 stars$2.51-5.3%$5.33+112.5%+89.3%$202.36M$147.56M14.76170Positive NewsDRUGBright Minds Biosciences3.3369 of 5 stars$28.32+9.1%$83.25+194.0%+2,469.4%$199.49MN/A-166.58N/APositive NewsAnalyst RevisionCRGXCARGO Therapeutics2.4275 of 5 stars$4.28+0.7%$15.00+250.5%-74.2%$197.35MN/A-1.00116Positive NewsIPHAInnate Pharma3.2977 of 5 stars$2.14-2.2%$11.00+413.8%-22.5%$197.35M$12.62M0.00220Positive NewsGap Down Related Companies and Tools Related Companies DBV Technologies Alternatives Aerovate Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Actuate Therapeutics Alternatives enGene Alternatives scPharmaceuticals Alternatives CytomX Therapeutics Alternatives Bright Minds Biosciences Alternatives CARGO Therapeutics Alternatives Innate Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOWL) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HOWL Stock Free HOWL Stock Alerts